Gynecology

Staging, Imaging, and Pathology Reports

At a Glance

Your cervical cancer stage reflects how far the tumor has grown and whether lymph nodes are involved, using examination, scans, and tissue analysis. MRI, PET/CT, and pathology reports provide different pieces of this picture, but no single test detects every cancer cell.

Understanding your cervical cancer diagnosis requires looking at three key pieces of information: the stage (how far it has spread), the imaging (pictures of the tumor), and the pathology report (the detailed lab analysis of the cells). These elements work together to help your care team determine the best treatment path for you.

The FIGO 2018 Staging System

Cervical cancer is staged using the FIGO (International Federation of Gynecology and Obstetrics) system. Unlike some other cancers, cervical cancer staging can be determined using physical exams, imaging, or pathology results ^[1]^[2]. Primary tumor stage and nodal stage are interpreted together, rather than being self-assigned from one measurement.

Understanding Stage IB (Size Matters)

Stage IB is a common diagnosis for invasive carcinoma that is confined to the cervix with a depth of invasion greater than 5 mm (disease up to 5 mm deep is Stage IA). Stage IB is subdivided specifically by the greatest dimension of the tumor:

Stage IB1: The tumor’s greatest dimension is less than 2 cm (about the size of a grape) ^[1].
Stage IB2: The tumor is between 2 cm and 4 cm ^[1].
Stage IB3: The tumor is 4 cm or larger ^[1].

Lymph Node Staging (Stage IIIC)

If cancer cells are found in the lymph nodes, the stage is classified as IIIC. The specific location of these nodes is critical because it dictates where radiation treatment needs to be targeted:

Stage IIIC1: Cancer has spread to the pelvic lymph nodes (nodes in the lower pelvis) ^[1]^[3].
Stage IIIC2: Cancer has spread to the para-aortic lymph nodes (nodes higher up, near the large artery in the abdomen) ^[1]^[3].
The “r” and “p” suffixes: You may see a small letter next to your stage. An “r” (e.g., IIIC1r) means the stage was determined by radiology/imaging. A “p” (e.g., IIIC1p) means it was confirmed by a pathologist looking at tissue under a microscope ^[1]^[4].

Imaging: Seeing the Details

Doctors use different types of scans to answer specific questions about the cancer. These tools are complementary, meaning one does not replace the other ^[5]^[6].

MRI (Magnetic Resonance Imaging): This is the best tool for looking closely at the cervix itself. It helps doctors see the exact size of the tumor and whether it has grown into nearby tissues like the parametria (the tissue surrounding the uterus), the vagina, or the bladder ^[7]^[8].
PET/CT (Positron Emission Tomography): This scan uses a small amount of radioactive sugar to find “active” areas in the body. It is primarily used to check if the cancer has spread to lymph nodes or distant organs ^[5]^[9].
Important Note: Imaging is not perfect. A negative PET/CT does not guarantee that microscopic cancer cells are absent. For this reason, depending on your stage and treatment plan (especially for selected early-stage patients undergoing surgery), your doctor may still recommend a surgical evaluation of the lymph nodes ^[10]^[11].

Your Pathology “Completeness Checklist”

The pathology report is the definitive “recipe” of your cancer. When you review your report, look for these essential details (note that items like margins and nodal status apply to surgical excisions like a cone biopsy or hysterectomy, and are not expected after a small diagnostic biopsy):

Component	What it Means
Histologic Subtype	Confirms if it is Squamous, Adenocarcinoma, or a rare type ^[12].
HPV Status	Notes if high-risk HPV was detected in the tumor (relevant for classifying selected histologies) ^[13].
Tumor Size	The largest dimension of the tumor in millimeters or centimeters ^[14].
Depth of Invasion	How deep the cancer has grown into the wall of the cervix ^[1]^[14].
LVSI	Lymphovascular Space Invasion; whether cancer cells have entered the small blood or lymph vessels. This is a risk factor for spread ^[15]^[16].
Margins	Whether the edges of the removed tissue are clear of cancer cells (when applicable) ^[14].
Nodal Status	The number of lymph nodes removed and how many (if any) contained cancer (when applicable) ^[17].

If any of these pieces are missing from an applicable report, it is a good idea to ask your doctor if more testing or information is needed to complete your “picture” ^[12].

Common questions in this guide

How is cervical cancer staged?

Cervical cancer is staged using the FIGO system, which describes how far the cancer has grown or spread. Doctors may use a physical examination, imaging, pathology, or a combination of these, and they interpret the primary tumor and lymph-node findings together.

What do cervical cancer stages IB1, IB2, and IB3 mean?

These are stage IB subcategories for invasive cervical cancer confined to the cervix with more than 5 mm of invasion. IB1 means the tumor is smaller than 2 cm, IB2 means it is 2 to 4 cm, and IB3 means it is 4 cm or larger based on its greatest dimension.

What is the difference between stage IIIC1 and IIIC2 cervical cancer?

Both stages mean that cervical cancer has spread to lymph nodes. IIIC1 refers to pelvic lymph nodes, while IIIC2 refers to para-aortic lymph nodes higher in the abdomen. The node location helps doctors determine where radiation should be directed.

What do the letters r and p mean after a cervical cancer stage?

An r means the stage was assigned using radiology or imaging findings. A p means the stage was confirmed by a pathologist examining tissue under a microscope.

Why might I need both an MRI and a PET/CT for cervical cancer?

MRI gives a detailed view of the cervix and can show the tumor's size and growth into nearby tissues. PET/CT is mainly used to look for cancer in lymph nodes or distant organs. The scans provide complementary information, so one does not replace the other.

Can a negative PET/CT rule out lymph node spread?

No. A negative PET/CT may not detect microscopic cancer cells. Depending on the stage and treatment plan, your doctor may still recommend a surgical lymph-node evaluation, such as a sentinel lymph-node biopsy.

What should I look for in my cervical cancer pathology report?

The report may include the cell type, high-risk HPV status, tumor size, depth of invasion, lymphovascular space invasion, margins, and lymph-node findings. Margins and nodal status are generally reported when tissue is removed during a procedure such as a cone biopsy or hysterectomy, rather than from a small diagnostic biopsy.

Get notified when new evidence is published on cervical cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (17)

1
Revised FIGO staging for carcinoma of the cervix uteri.
Bhatla N, Berek JS, Cuello Fredes M, et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2019; (145(1)):129-135 doi:10.1002/ijgo.12749.
PMID: 30656645
2
Current FIGO Staging for Carcinoma of the Cervix Uteri and Treatment of Particular Stages.
Sehnal B, Kmoníčková E, Sláma J, et al.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2019; (32(3)):224-231 doi:10.14735/amko2019224.
PMID: 31216857
3
Cervical Cancer: 2018 Revised International Federation of Gynecology and Obstetrics Staging System and the Role of Imaging.
Saleh M, Virarkar M, Javadi S, et al.
AJR. American journal of roentgenology 2020; (214(5)):1182-1195 doi:10.2214/AJR.19.21819.
PMID: 32182097
4
Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines.
Wright JD, Matsuo K, Huang Y, et al.
Obstetrics and gynecology 2019; (134(1)):49-57 doi:10.1097/AOG.0000000000003311.
PMID: 31188324
5
What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?
Haldorsen IS, Lura N, Blaakær J, et al.
Current oncology reports 2019; (21(9)):77 doi:10.1007/s11912-019-0824-0.
PMID: 31359169
6
Multimodality Imaging of Uterine Cervical Malignancies.
Mansoori B, Khatri G, Rivera-Colón G, et al.
AJR. American journal of roentgenology 2020; (215(2)):292-304 doi:10.2214/AJR.19.21941.
PMID: 32551909
7
Diagnostic performance of conventional and advanced imaging modalities for assessing newly diagnosed cervical cancer: systematic review and meta-analysis.
Woo S, Atun R, Ward ZJ, et al.
European radiology 2020; (30(10)):5560-5577 doi:10.1007/s00330-020-06909-3.
PMID: 32415584
8
Diagnostic efficiency of whole-body 18F-FDG PET/MRI, MRI alone, and SUV and ADC values in staging of primary uterine cervical cancer.
Steiner A, Narva S, Rinta-Kiikka I, et al.
Cancer imaging : the official publication of the International Cancer Imaging Society 2021; (21(1)):16 doi:10.1186/s40644-020-00372-5.
PMID: 33482909
9
FDG-PET Imaging in Cervical Cancer.
Gandy N, Arshad MA, Park WE, et al.
Seminars in nuclear medicine 2019; (49(6)):461-470 doi:10.1053/j.semnuclmed.2019.06.007.
PMID: 31630730
10
PET-CT versus MRI in the diagnosis of lymph node metastasis of cervical cancer: A meta-analysis.
He T, Sun J, Wu J, et al.
Microscopy research and technique 2022; (85(5)):1791-1798 doi:10.1002/jemt.24039.
PMID: 34981608
11
The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023).
Fischerova D, Frühauf F, Burgetova A, et al.
Cancers 2024; (16(4)) doi:10.3390/cancers16040775.
PMID: 38398166
12
Dataset for the Reporting of Carcinoma of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
Park KJ, Selinger CI, Alvarado-Cabrero I, et al.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2022; (41(Suppl 1)):S64-S89 doi:10.1097/PGP.0000000000000909.
PMID: 36305535
13
Invasive Squamous Cell Carcinoma of the Cervix: A Review of Morphological Appearances Encountered in Human Papillomavirus-associated and Papillomavirus-independent Tumors and Precursor Lesions.
Stolnicu S, Allison D, Patrichi A, et al.
Advances in anatomic pathology 2024; (31(1)):1-14 doi:10.1097/PAP.0000000000000411.
PMID: 37638549
14
Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.
Kang S, Wu J, Li J, et al.
Medical science monitor : international medical journal of experimental and clinical research 2022; (28()):e934588 doi:10.12659/MSM.934588.
PMID: 35260545
15
The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients.
Ronsini C, Anchora LP, Restaino S, et al.
Gynecologic oncology 2021; (162(2)):299-307 doi:10.1016/j.ygyno.2021.06.002.
PMID: 34116834
16
Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: A retrospective study.
Yan W, Qiu S, Ding Y, et al.
Medicine 2019; (98(40)):e17301 doi:10.1097/MD.0000000000017301.
PMID: 31577720
17
[Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes].
Höhn AK, Brambs CE, Erber R, et al.
Der Pathologe 2021; (42(3)):319-327 doi:10.1007/s00292-020-00805-9.
PMID: 32700061

This page is for informational purposes only and does not constitute medical advice. Your cervical cancer care team should interpret your reports and recommend care for your individual situation.

Guide Contents